Gastón Picchio

9.3k total citations
156 papers, 5.3k citations indexed

About

Gastón Picchio is a scholar working on Hepatology, Infectious Diseases and Epidemiology. According to data from OpenAlex, Gastón Picchio has authored 156 papers receiving a total of 5.3k indexed citations (citations by other indexed papers that have themselves been cited), including 88 papers in Hepatology, 81 papers in Infectious Diseases and 66 papers in Epidemiology. Recurrent topics in Gastón Picchio's work include Hepatitis C virus research (87 papers), HIV/AIDS drug development and treatment (74 papers) and HIV Research and Treatment (42 papers). Gastón Picchio is often cited by papers focused on Hepatitis C virus research (87 papers), HIV/AIDS drug development and treatment (74 papers) and HIV Research and Treatment (42 papers). Gastón Picchio collaborates with scholars based in United States, Belgium and Germany. Gastón Picchio's co-authors include Donald E. Mosier, Johan Vingerhoets, R. Gallino, M. Busso, C. M. Raiteri, Sandra De Meyer, Marie‐Pierre de Béthune, L Rimsky, Maria Beumont and Tara L. Kieffer and has published in prestigious journals such as Nature, Immunity and Gastroenterology.

In The Last Decade

Gastón Picchio

153 papers receiving 5.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Gastón Picchio United States	41	2.5k	2.4k	2.4k	1.9k	586	156	5.3k
R.H. Miller United States	51	1.4k 0.6×	6.1k 2.6×	6.2k 2.6×	762 0.4×	558 1.0×	220	11.4k
Dirk Schürmann Germany	27	1.0k 0.4×	400 0.2×	1.2k 0.5×	600 0.3×	178 0.3×	115	2.8k
Matthew J. Dolan United States	48	2.0k 0.8×	182 0.1×	1.1k 0.5×	2.8k 1.5×	2.1k 3.5×	143	7.7k
George W. Nelson United States	42	1.3k 0.5×	203 0.1×	878 0.4×	2.3k 1.2×	3.2k 5.5×	78	8.7k
Daniel Berger United States	38	1.2k 0.5×	270 0.1×	798 0.3×	938 0.5×	51 0.1×	117	6.2k
Yoshiki Murakami Japan	35	183 0.1×	1.5k 0.6×	1.7k 0.7×	43 0.0×	392 0.7×	158	5.5k
François Pénin France	49	1.1k 0.4×	5.8k 2.4×	4.5k 1.9×	892 0.5×	645 1.1×	122	8.2k
James W. Young United States	52	576 0.2×	109 0.0×	1.7k 0.7×	303 0.2×	6.5k 11.2×	189	11.1k
J. E. Drummond United States	23	431 0.2×	120 0.1×	269 0.1×	331 0.2×	444 0.8×	55	1.7k
S. Church United States	22	277 0.1×	46 0.0×	209 0.1×	354 0.2×	1.4k 2.4×	89	3.0k

Countries citing papers authored by Gastón Picchio

Since Specialization

Citations

This map shows the geographic impact of Gastón Picchio's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gastón Picchio with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gastón Picchio more than expected).

Fields of papers citing papers by Gastón Picchio

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gastón Picchio. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gastón Picchio. The network helps show where Gastón Picchio may publish in the future.

Co-authorship network of co-authors of Gastón Picchio

This figure shows the co-authorship network connecting the top 25 collaborators of Gastón Picchio. A scholar is included among the top collaborators of Gastón Picchio based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gastón Picchio. Gastón Picchio is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Yuen, Man‐Fung, Elina Berliba, Wattana Sukeepaisarnjaroen, et al.. (2022). Safety, pharmacokinetics, and antiviral activity of the capsid inhibitor AB‐506 from Phase 1 studies in healthy subjects and those with hepatitis B. Hepatology Communications. 6(12). 3457–3472. 17 indexed citations

Villamil, Federico, et al.. (2021). Twenty-year follow-up of an outbreak of hepatitis C in a small rural town of Argentina: The O'Brien Project. Annals of Hepatology. 27. 100577–100577. 1 indexed citations

Berg, Thomas, Pietro Andreoné, Stanislas Pol, et al.. (2014). Low‐density lipoprotein and other predictors of response with telaprevir‐based therapy in treatment‐experienced HCV genotype 1 patients: REALIZE study. Liver International. 35(2). 448–454. 5 indexed citations

Picchio, Gastón, Sandra De Meyer, Inge Dierynck, et al.. (2014). Patterns of viral load decline with telaprevir-based therapy in patients with genotype 1 chronic HCV infection. Journal of Clinical Virology. 59(3). 148–155. 1 indexed citations

Meyer, Sandra De, Anne Ghys, Inge Dierynck, et al.. (2014). Virologic characterization of genotype 4 hepatitis C virus variants in patients treated with telaprevir. Virology Journal. 11(1). 93–93. 4 indexed citations

Sarrazin, C., H.W. Reesink, Stefan Zeuzem, et al.. (2013). 898 TREATMENT WITH TELAPREVIR/PEG-IFN/RBV AFTER 14-DAY TELAPREVIR EXPOSURE IN PHASE I STUDIES: RESULTS FROM THE PHASE IIIB C219 ROLLOVER STUDY. Journal of Hepatology. 58. S369–S370. 3 indexed citations

Sullivan, James C., Sandra De Meyer, Doug J. Bartels, et al.. (2013). Evolution of Treatment-Emergent Resistant Variants in Telaprevir Phase 3 Clinical Trials. Clinical Infectious Diseases. 57(2). 221–229. 114 indexed citations

Lenz, Oliver, Leen Vijgen, Jan Martin Berke, et al.. (2012). Virologic response and characterisation of HCV genotype 2–6 in patients receiving TMC435 monotherapy (study TMC435-C202). Journal of Hepatology. 58(3). 445–451. 69 indexed citations

Zeuzem, Stefan, Pietro Andreoné, Stanislas Pol, et al.. (2011). 5 REALIZE TRIAL FINAL RESULTS: TELAPREVIR-BASED REGIMEN FOR GENOTYPE 1 HEPATITIS C VIRUS INFECTION IN PATIENTS WITH PRIOR NULL RESPONSE, PARTIAL RESPONSE OR RELAPSE TO PEGINTERFERON/RIBAVIRIN. Journal of Hepatology. 54. S3–S3. 23 indexed citations

10.

Foster, Graham R., Stefan Zeuzem, Pietro Andreoné, et al.. (2011). 6 SUBANALYSES OF THE TELAPREVIR LEAD-IN ARM IN THE REALIZE STUDY: RESPONSE AT WEEK 4 IS NOT A SUBSTITUTE FOR PRIOR NULL RESPONSE CATEGORIZATION. Journal of Hepatology. 54. S3–S4. 21 indexed citations

11.

Foster, Graham R., Stefan Zeuzem, Pietro Andreoné, et al.. (2011). OP03 Telaprevir-based therapy in G1 HCV-infected patients with prior null response, partial response or relapse to peginterferon/ribavirin: REALIZE trial final results: Abstract OP03 Table 1. Gut. 60(Suppl 2). A50.3–A51. 5 indexed citations

12.

Lenz, Oliver, Bart Fevery, Leen Vijgen, et al.. (2011). TMC435 IN COMBINATION WITH PEGINTERFERON ALPHA-2A/RIBAVIRIN IN TREATMENT-NAiVE PATIENTS INFECTED WITH HCV GENOTYPE 1: VIROLOGY ANALYSIS OF THE PILLAR STUDY. Hepatology. 54. 8 indexed citations

13.

Picchio, Gastón, Johan Vingerhoets, Lotke Tambuyzer, et al.. (2011). Short Communication Prevalence of Susceptibility to Etravirine by Genotype and Phenotype in Samples Received for Routine HIV Type 1 Resistance Testing in the United States. AIDS Research and Human Retroviruses. 27(12). 1271–1275. 16 indexed citations

14.

Kulkarni, Rima, Kerim Babaoglu, E.B. Lansdon, et al.. (2011). The HIV-1 Reverse Transcriptase M184I Mutation Enhances the E138K-Associated Resistance to Rilpivirine and Decreases Viral Fitness. JAIDS Journal of Acquired Immune Deficiency Syndromes. 59(1). 47–54. 69 indexed citations

15.

Meyer, Sandra De, et al.. (2010). 251 GENOTYPIC AND PHENOTYPIC CHARACTERIZATION OF GENOTYPE 2/3 HCV VARIANTS IN PATIENTS TREATED WITH TELAPREVIR ALONE OR IN COMBINATION WITH PEGINTERFERON ALFA-2A/RIBAVIRIN IN STUDY C209. Journal of Hepatology. 52. S106–S106. 1 indexed citations

16.

Tambuyzer, Lotke, Johan Vingerhoets, Hilde Azijn, et al.. (2010). Characterization of Genotypic and Phenotypic Changes in HIV-1-Infected Patients with Virologic Failure on an Etravirine-Containing Regimen in the DUET-1 and DUET-2 Clinical Studies. AIDS Research and Human Retroviruses. 26(11). 1197–1205. 45 indexed citations

17.

Vingerhoets, Johan, Hilde Azijn, Lotke Tambuyzer, et al.. (2010). Short Communication: Activity of Etravirine on Different HIV Type 1 Subtypes: In Vitro Susceptibility in Treatment-Naive Patients and Week 48 Pooled DUET Study Data. AIDS Research and Human Retroviruses. 26(6). 621–624. 11 indexed citations

18.

Meyer, Sandra De, Erkki Lathouwers, Inge Dierynck, et al.. (2009). Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients. AIDS. 23(14). 1829–1840. 46 indexed citations

19.

Meyer, Sandra De, Tony Vangeneugden, Ben Van Baelen, et al.. (2008). Resistance Profile of Darunavir: Combined 24-Week Results from the POWER Trials. AIDS Research and Human Retroviruses. 24(3). 379–388. 121 indexed citations

20.

Rochford, Rosemary, Martin J. Cannon, Rebecca Sabbe, et al.. (1997). Common and Idiosyncratic Patterns of Cytokine Gene Expression by Epstein-Barr Virus Transformed Human B Cell Lines. Viral Immunology. 10(4). 183–195. 40 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact